UBS analyst Trung Huynh raised the firm’s price target on Regeneron (REGN) to $584 from $560 and keeps a Neutral rating on the shares. UBS is 2% above consensus for Q2 financials, driven by positive expectations for the Eylea franchise, the analyst tells investors in a research note. The firm views current valuation as fairly reflecting the mixed risk/rewards in near-term.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Regeneron Advances in Lung Cancer Immunotherapy with New Clinical Study
- Regeneron’s Latest Melanoma Study: A Potential Game-Changer?
- Regeneron’s Phase 3 Trial: A New Hope for Lymphoma Treatment?
- Regeneron and Sanofi’s Dupilumab Study: A Potential Breakthrough for Lichen Simplex Chronicus
- Regeneron price target lowered to $754 from $755 at Morgan Stanley